Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Other Accumulated Expenses (2018 - 2025)

Assembly Biosciences has reported Other Accumulated Expenses over the past 8 years, most recently at $7.7 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $7.7 million for Q4 2025, up 240.92% from a year ago — trailing twelve months through Dec 2025 was $7.7 million (up 240.92% YoY), and the annual figure for FY2025 was $7.7 million, up 240.92%.
  • Other Accumulated Expenses for Q4 2025 was $7.7 million at Assembly Biosciences, up from $3.1 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for ASMB hit a ceiling of $7.7 million in Q4 2025 and a floor of $885000.0 in Q4 2023.
  • Median Other Accumulated Expenses over the past 5 years was $3.6 million (2021), compared with a mean of $3.9 million.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 87.9% in 2023 and later surged 240.92% in 2025.
  • Assembly Biosciences' Other Accumulated Expenses stood at $3.4 million in 2021, then surged by 115.21% to $7.3 million in 2022, then tumbled by 87.9% to $885000.0 in 2023, then skyrocketed by 156.84% to $2.3 million in 2024, then surged by 240.92% to $7.7 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $7.7 million (Q4 2025), $3.1 million (Q3 2025), and $3.4 million (Q2 2025) per Business Quant data.